A Ready-Mixed Wrinkle Relaxer Was Turned Down by the FDA Again: What It Means for Las Vegas

Galderma's relabotulinumtoxinA, sold overseas as Relfydess, is not FDA approved. The FDA declined it a second time on June 29, 2026. Here's a plain-language look at what's actually been confirmed so far, and why it's worth watching rather than rushing.

What Actually Got Accepted by the FDA

In February 2026, Galderma announced that the FDA had taken back up its application for a neuromodulator called relabotulinumtoxinA, aimed at softening frown lines between the brows and crow's feet at the outer eye. This wasn't the company's first attempt. An earlier submission had been turned back in 2023, but only over questions about manufacturing consistency, not the drug's safety or how well it worked.

Getting an application accepted for review is a meaningful step, though it isn't the same as approval. That distinction turned out to matter: on June 29, 2026, the FDA issued a second Complete Response Letter, so the application is not under review now. Galderma has said it worked directly with regulators to adjust its production process before resubmitting, and the company has not shared a firm timeline for when, or if, a final decision and U.S. launch might follow.

Why Skipping the Mixing Step Is a Bigger Deal Than It Sounds

Every neuromodulator currently used in Las Vegas med spas, from the household names to the newer options, starts as a powder that an injector has to reconstitute with saline before each session. That mixing step introduces room for small variations from one vial, or one provider, to the next.

RelabotulinumtoxinA is built to skip that entirely. Galderma manufactures it as a ready-to-use liquid using an in-house process the company calls PEARL Technology, meant to help the molecule stay intact through storage and shipping. In theory, a premixed product could mean steadier dosing from appointment to appointment, though how that plays out once it's in wide clinical use will only become clear over time.

What the Study Numbers Actually Show

Galderma's supporting research, called the READY program, spanned four separate late-stage trials with a combined total of more than 1,900 participants. Some volunteers reported noticing a visible change as soon as the first day after treatment, faster than the several days it typically takes standard neuromodulators to take effect.

On the other end, reported effects were tracked out toward roughly six months for both treatment areas in follow-up, longer than the three to four months most patients are used to with existing options today. Individual results in any trial vary widely from person to person, and how a treatment performs in a controlled study is not a promise of what any one patient will experience.

What This Means for a Las Vegas Med Spa Visit Right Now

Relabotulinumtoxina is already cleared in more than twenty markets abroad, including the European Union, the United Kingdom, and parts of Asia and Australia, so international patients may already be familiar with the Relfydess name. In the United States, though, it remains an investigational product with no confirmed launch window.

• It is not yet approved or available for use in the U.S., including here in Las Vegas.
• There's no set date. Galderma must resubmit within one year of the June 29, 2026 letter before the FDA reviews it again.
• Once (and if) it does launch, pricing, provider training, and availability will take time to settle in locally.

Questions Worth Asking Before Any New Neuromodulator Reaches the Menu

Whenever a new injectable option starts making headlines, it's tempting to want it immediately. Here's what's genuinely useful to ask your provider, whether about this product or the next one that comes along.

1. Is it actually FDA approved yet?: Headlines about applications, trials, and acceptances are not the same as approval. Ask directly whether a product is cleared for use in the U.S. before assuming it's an option.
2. How does the onset compare to what you already use?: Faster reported onset in a trial setting doesn't automatically mean a faster visit for you. Ask your injector how it compares to your current routine.
3. What does 'ready-to-use' change for me as a patient?: A premixed formula is mostly a manufacturing and consistency story. Ask whether it's expected to affect your dosing, comfort, or appointment length.
4. How long do effects typically last?: Duration estimates come from group averages in trials. Ask your provider what a realistic range looks like for someone with your history and goals.
5. Has your practice used it or trained on it yet?: Even after approval, it takes time for products to reach local shelves and for injectors to build hands-on experience with them.
6. Is switching from your current treatment even worth it?: A newer option isn't automatically the better fit. Ask what would actually change for your specific concerns before considering a switch.

← More from the Bella Med Spa blog